C erebral hypoxic-ischemic (HI) events have major consequences on neurological functions, leading to long-term sequelae 1 in adults and newborns. Perinatal complications associated with hemodynamic compromise, proinflammatory states, hypercapnia, and hyperoxia have all been associated with diffuse microvascular degeneration and brain injury. 2,3 These insults substantially increase the risk of neonatal encephalopathies and life-long neurological disabilities, including cerebral palsy, mental retardation, and epilepsy. 4 Several studies have emphasized the role of oxidants on the genesis of HI brain injuries. 5 In recent years, increased interest in regenerative biology has motivated the importance of tackling the recovery phase after HI. [6] [7] [8] This recovery process entails different facets, including neurogenesis, synaptic remodeling, and of paramount importance-angiogenesis. Hence, this implies that the brain harbors innate reparative capabilities. [9] [10] [11] In this context, prompt revascularization of stroke is associated with improved outcome. [12] [13] [14] For instance in humans, elevated levels of vascular endothelial growth factor (VEGF) are observed after stroke, and increased microvascular density correlates with a better outcome. 15, 16 In animal models, intracerebral injections of proangiogenic factors greatly enhance motor functions. 17 Given the profound metabolic changes that occur in response to HI-associated cerebrovascular compromise, it would be surprising that these are not related to reinstate energy status possibly by governing expression of critical angiogenic factors. A better elucidation of mechanisms implicated in post-HI revascularization would enable to propose Objective-Prompt post-hypoxia-ischemia (HI) revascularization has been suggested to improve outcome in adults and newborn subjects. Other than hypoxia-inducible factor, sensors of metabolic demand remain largely unknown. During HI, anaerobic respiration is arrested resulting in accumulation of carbohydrate metabolic intermediates. As such succinate readily increases, exerting its biological effects via a specific receptor, G-protein-coupled receptor (GPR) 91. We postulate that succinate/GPR91 enhances post-HI vascularization and reduces infarct size in a model of newborn HI brain injury. Approach and Results-The Rice-Vannucci model of neonatal HI was used. Succinate was measured by mass spectrometry, and microvascular density was evaluated by quantification of lectin-stained cryosection. Gene expression was evaluated by real-time polymerase chain reaction. Succinate levels rapidly increased in the penumbral region of brain infarcts. GPR91 was foremost localized not only in neurons but also in astrocytes. Microvascular density increased at 96 hours after injury in wild-type animals; it was diminished in GPR91-null mice leading to an increased infarct size. Stimulation with succinate led to an increase in growth factors implicated in angiogenesis only in wild-type mice. To explain the mode of action of succinate/GPR91, we investigated the role of prostaglandin E 2 -prostaglandin E receptor 4, previously proposed in neural angiogenesis. Succinate-induced vascular endothelial growth factor expression was abrogated by a cyclooxygenase inhibitor and a selective prostaglandin E receptor 4 antagonist. This antagonist also abolished succinate-induced neovascularization. Conclusions-We uncover a dominant metabolic sensor responsible for post-HI neurovascular adaptation, notably succinate/ GPR91, acting via prostaglandin E 2 -prostaglandin E receptor 4 to govern expression of major angiogenic factors. We propose that pharmacological intervention targeting GPR91 could improve post-HI brain recovery. (Arterioscler Thromb Vasc Biol. 2014;34:285-293.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
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timely approaches for neuroprotection 18, 19 by reestablishing appropriate vascular supply and hence metabolic balance.
Hypoxia leads to arrest in anaerobic respiration resulting in accumulation of carbohydrate metabolites involved in energy formation. Many of these metabolic intermediates are Krebs cycle metabolites, notably succinate, which have been reported to exert vasorelaxant and angiogenic properties. [20] [21] [22] Yet, their mode of action has generally remained inexplicable, until membrane-bound receptors that are specifically activated by these metabolites have been identified. 23 In this context, succinate has been shown to contribute to the developmental and possibly aberrant retinal neovascularization presumably through actions on G-protein-coupled receptor (GPR) 91 independent of hypoxia-inducible factor activation 24 ; accordingly, siRNAand shRNA-GPR91 interfere with developmental angiogenesis and partly with abnormal preretinal neovascularization.
Nonstandard Abbreviations and Acronyms EP4 prostaglandin E receptor 4 GPR G-protein-coupled receptor HI hypoxia-ischemia VEGF Vascular endothelial growth factor Figure 1 . Succinate accumulates in the penumbral region after cerebral hypoxia-ischemia (HI) where G-protein-coupled receptor (GPR) 91 is expressed in neurons and astrocytes. A, GPR91 colocalizes with NeuN (i) and glial fibrillary acidic protein (GFAP) (ii) in the rat cerebral cortex. Rabbit anti-GPR91 was used to label GPR91, and mouse anti-NeuN-a neuronal marker-was used to mark neurons. Colocalization with astrocytes was determined with mouse anti-GFAP. 4',6-diamidino-2-phenylindole (DAPI) was used to stain nuclei (scale bar, 25 μm). B, Semiquantitative polymerase chain reaction from cerebral cortex, cortical neurons, astrocytes, and cell lines retinal ganglion cells (RGC-5)-5, rat cerebral astrocytes (RCA), and rat brain microvascular endothelial cells (RBMEC) was used to evaluate GPR91 mRNA abundance. β-Actin was used as a loading control (i). Sample lysates from cerebral cortex, cortical neurons, astrocytes, and cell lines RGC-5, RCA, and RBMEC were subjected to SDS-PAGE and Western blotting with anti-GPR91 or anti-β-actin antibodies as indicated (ii). C, Rat cortical section stained with DAPI demonstrating the region (*) on which we focused throughout this study. D, Kinetic analysis of succinate concentration in animals subjected to HI shows a significant increase immediately after exposure to hypoxia and a return to baseline within 60 minutes (n=3; ***P<0.001).
Although an increase in hypoxia-inducible factor has been detected in brain after HI, 25 the post-HI brain revascularization seems to be independent of hypoxia-inducible factor. 26 Hence, mechanisms that orchestrate post-HI vascularization in the brain remain unknown. We postulate that succinate via GPR91 acts as a central sensor governing the release of (numerous) proangiogenic factors after neonatal HI brain insults and in turn diminishing infarct size. We hereby confirm this novel hypothesis and show that succinate-/GPR91-induced expression of major proangiogenic factors, notably VEGF, is regulated via a prostaglandin E 2 (PGE 2 )-/prostaglandin E receptor 4 (EP 4 )-dependent mechanism.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Succinate Accumulates in the Cerebral Cortex Expressing GPR91
The succinate receptor GPR91 was detected in the cerebral cortex of control animals primarily in neurons (colocalization with NeuN; Figure 1A ). GPR91 mRNA and protein expression were confirmed with isolated cortical neurons, as well as with cultured retinal ganglion cell (RGC5) and rat cerebral astrocyte (RCA) neuronal cell lines ( Figure 1B) . A weaker expression of GPR91 was also found on primary isolated astrocytes and a rodent cortical astrocyte cell line ( Figure 1B) ; GPR91 was not detected on brain endothelial cells. In the cortical region corresponding to the penumbra ( Figure 1C ), we observed a 3-fold increase in succinate concentration 90 minutes after subjecting wild-type ( Figure 1D ) and GPR91-null ( Figure I in the online-only Data Supplement) mouse pups to HI; this increase subsided to basal levels 1 hour later.
Succinate and GPR91 Augment Cortical Vascular Density and Preserve Brain Parenchyma After Perinatal HI Insult
We investigated the role of succinate/GPR91 in brain revascularization and post-HI preservation of brain parenchyma. HI injury induced a gradual decrease in microvascular density in (corresponding) cortical penumbral region detected at 24 hours, followed by an increase in vascular density at 96 hours post-HI ( Figure 2Ai and 2Aii); evidently, vessels and parenchyma were fully destroyed in the infarct core (not shown).
For the first 24 hours post-HI, microvascular density also decreased in GPR91-null mice, but vessel density remained low at 96 hours in these animals ( Figure 2Ai and 2Aii). Accordingly, the volume of the infarct core and of the (metabolically compromised) penumbra was markedly (≈3-fold) larger in GPR91-null mice when compared with wild-type animals, especially at 96 hours post-HI ( Figure 2B ). It should also be noted that vascular density was comparable in intact wild-type and GPR91-null animals between postnatal day (P) 7 and P11 ( Figure II in the online-only Data Supplement). Figure 2 . G-protein-coupled receptor (GPR) 91 regulates blood formation and infarct size after hypoxia-ischemia (HI). A, Representative photomicrograph of vascular density 96 hours after HI in mice (i; scale bar, 25 μm). GPR91 -/vascular density inadequately recovered and remains 30% inferior to wild-type (WT) mice as measured on lectin-stained cryosections (n=6; ***P<0.001, **P<0.01). No difference in normal vascularization at postnatal day (P) 11 is observed between WT and GPR91 -/mice. Hypoxia alone (no ligation) does not cause noticeable degeneration (ii). Western blot analysis demonstrating expression of GPR91 in WT mice and its absence in GPR91 -/mice (iii). B, Damages evaluated by 2,3,5-triphenyltetrazolium chloride at 24 and 96 hours post-HI shows the reduction in vascular supply is correlated with a change in infarct size, in GPR91 -/mice, in the penumbra and core, respectively (n=5-7; *P<0.05, ***P<0.001; i). Representative infarct in mice. Yellow lines delineate infarct core (white) and penumbral (pink) regions (ii). February 2014
To substantiate the actions of GPR91 on brain angiogenesis, succinate (at concentrations equivalent to those detected in HI) was injected intracerebroventricularly before HI insult; succinate reduced penumbral and core infarct sizes by ≈50% at 96 hours post-HI ( Figure 3A ). To ascertain cerebral angiogenic effects of succinate further, the latter was injected intracerebroventricularly at P7 in intact wild-type and GPR91-null mice; succinate nearly doubled microvascular density measured at P11 in wild-type animals but not in GPR91-null mice ( Figure 3B ). Likewise, treatment of cortical explants ( Figure 3Ci ) with succinate also led to an equivalent increase in microvascular density (Figure 3Cii ); succinate was ineffective on cortical explants from GPR91null mice (Figure 3Ciii ).
GPR91 Controls the Expression of Numerous Angiogenic Factors
We evaluated the propensity of GPR91 to regulate the expression of key proangiogenic genes in the post-HI recovery process. Intracerebroventricular injection of succinate caused a time-dependent expression of the major proangiogenic factor VEGF in brain of wild-type mice, which peaked at 24 hours ( Figure 4A , inset). Concomitantly, we observed an increase in angiopoetin 1, angiopoetin 2, and angiogenic inflammatory mediators interleukin-1β and interleukin-6. 27 In contrast, no increase in any of these factors was detected in brain of GPR91-null mice treated with succinate ( Figure 4A ). Similarly, VEGF, angiopoetin 1, angiopoetin 2, interleukin-1, and interleukin-6 increased 24 hours after HI insult in brain of wild-type mice ( Figure 4B ); these increases were significantly attenuated in GPR91-null mice. Correspondingly, induction of these major angiogenic genes was also detected 4 hours after succinate stimulation of RGC and RCA to values somewhat equivalent to those after hypoxia (4% O 2 ; Figure 4C ; Figure 
Role of Prostaglandin Signaling in Response to GPR91-Dependent VEGF Expression
We proceeded to explore mechanisms for GPR91 induction of major angiogenic factors in brain cells. GPR91 has been reported to signal via PGE 2 and extracellular signal-regulated kinase-1/2 in renal cells. 28 We investigated whether succinate induced these signals in neurons and glia, which express GPR91, specifically in RGC and RCA cells ( Figure 1A) . Succinate induced a rapid and transient activation of extracellular signal-regulated kinase-1/2 (Figure 5Ai and 5Aii) , which was not observed in cells infected with a lentivirus encoding a reported shRNA-GPR91, 24 confirming again dependence on GPR91 ( Figure IVB in the online-only Data Supplement). Succinate also increased PGE 2 concentrations in RGC ( Figure  5Aii ) and RCA ( Figure VA in the online-only Data Supplement) cell lines. However, extracellular signal-regulated kinase inhibitors did not affect succinate-induced VEGF expression ( Figure 5B) ; the same was observed with disruptors of hypoxia-inducible factor, 29 consistent with reported lack of its role in this process. 24 Inhibition of prostaglandin synthesis with indomethacin abrogated succinate-induced VEGF expression ( Figure 5B ; Figure VB in the online-only Data Supplement). Along these lines, prostaglandin levels are long known to increase in HI brain insult, 30 and more specifically EP 4 has been shown to exert a role in promoting angiogenesis [31] [32] [33] [34] [35] by upregulating VEGF expression. 36, 37 Therefore, we evaluated the contribution of the PGE 2 -EP 4 axis in GPR91-dependent biochemical processes of brain vascularization.
To ascertain that prostaglandins are also generated in vivo in response to succinate, we first measured the levels of PGE 2 after intracerebroventricular injection of succinate. We detected a time-dependent rise in brain PGE 2 in wild-type mice, which significantly increased by 60 minutes after succinate ( Figure 5C ); succinate was ineffective in raising PGE 2 levels in GPR91-null mice. We then showed in RGC (as well as in RCA; Figure VB in the online-only Data Supplement) that succinate-induced VEGF was abolished by selective EP 4 antagonist L-161982 38 but not by the EP 1,2,3 antagonist AH6809 39 ( Figure 5B) ; concordantly, PGE 2 increased VEGF expression in a dose-dependent manner ( Figure VC in the online-only Data Supplement). Finally, more relevantly, we demonstrated that GPR91-dependent (Figures 2 and 4) succinate-induced brain VEGF expression and increased microvascular density in vivo were markedly attenuated by L-161982 ( Figure 5D ). Together, these results indicate a major role for EP 4 in succinate-/GPR91-induced angiogenesis.
Discussion
The neonatal brain is particularly susceptible to HI insults. In this context, the vasculature of the newborn brain is vulnerable to damage, and its degeneration precedes that of parenchymal cells, as demonstrated under various adverse conditions regularly encountered by premature subjects, such as hyperoxia (relative to values in utero O 2 ), 2 hypercapnia (frequently observed with chronic lung disease of the premature infant), 40 and in HI insults. 3 Therefore, we used the Rice-Vannucci rodent pup model of HI encephalopathy because the development of brain white matter and supporting vasculature of rodents is gestationally delayed relative to that of the human and increases after birth for the first 12 postnatal days. 41, 42 Despite widespread brain injury often encountered in the neonatal brain, remarkable recovery is observed. 43, 44 This brain recovery of course requires an orchestrated angiogenesis. [45] [46] [47] Accordingly, mechanisms that sense the early local HI would be critical to trigger a process of revascularization and repair. Because carbohydrate metabolites of the Krebs cycle, notably succinate, 48 accumulate under HI conditions, these metabolites have been proposed as preconditioning molecules. 49 The discovery of a specific receptor for succinate, namely GPR91, 23 led us to explore its role in post-HI brain vascularization. In this study, we demonstrate for the first time, the essential role played by GPR91 in sensing hypoxic stress during cerebral HI and the benefits of its activation in preserving tissue integrity by stimulating angiogenesis by governing the expression of numerous proangiogenic factors, including VEGF. We also show that this angiogenic gene regulation is dependent on a succinate-induced generation of PGE 2 acting specifically via its EP 4 receptor. Collectively the data reveal that succinate/GPR91 signaling plays a determining role in post-HI cerebral revascularization and brain recovery and provides a novel link through which metabolic intermediates acting via specific receptors participate in post-HI cerebrovascular functions by reinstating energy supply.
Succinate and other energy intermediates have been extensively studied in the last decades; however, this was mostly in the context of energy production. Only recently was it demonstrated that succinate, via a specific receptor GPR91, can induce physiological changes beyond its well-documented role in metabolism, in which rising concentrations after hypoxic events can trigger specific cell functions. 23 Metabolic intermediates have been largely overlooked in the study of poststroke recovery, despite results showing concentration fluctuations during cerebral hypoxia since the 1970s. 20 Lactate Figure 5 . Involvement of prostaglandin E 2 (PGE 2 ) and prostaglandin E receptor 4 (EP 4 ) in G-protein-coupled receptor (GPR) 91 signaling. A, Stimulation of retinal ganglion cells-5 with 100 μmol/L succinate leads to induction of extracellular signal-regulated kinase (ERK)1/2 phosphorylation (i). Fold activation of ERK1/2 activation (ii; n=3, **P<0.01). Similarly, PGE 2 can be detected in RGC-5 cell lysates (iii; n=3; *P<0.05). B, Vascular endothelial growth factor (VEGF) mRNA expression after stimulation of RGC-5 cells with succinate is strongly affected by cyclooxygenase inhibitor indomethacin (100 μmol/L; Indo), and EP 4 antagonist L-161 (L-161982) (10 μmol/L); concentrations reported to be effective were used. 38 No effects are observed with multispecific EP 1,2,3 antagonist (AH6809; 1.5×10 -5 mol/L ) or with hypoxia-inducible factor (HIF)-1a/2a antagonist FM19G11 (FM) or ERK1/2 inhibitor PD98059 (PD; 50 μmol/L; n=6; *P<0.05, ***P<0.001); effective concentrations were used as reported. 29, 39 Stimulation of RGC-5 for 4 hours with PGE 2 induces expression of VEGF mRNA in a dose-dependent fashion (n=3; *P<0.05, **P<0.01; inset). C, Measurement of PGE 2 in brain tissue of wild-type (WT) and GPR91 -/mice at different time-point after intracerebroventricular injection of succinate. Significant increase is noted only in WT mice at 60 minutes after the injection (n=4; **P<0.01). D, In vivo, intracerebroventricular injection of succinate induces VEGF mRNA in WT mice that is strongly affected when coinjected with EP 4 antagonist L-161982 (estimated final concentration of 10 μmol/L; i) This effect on the gene induction is paralleled by corresponding differences in vascular density (ii; n=5-10; *P<0.05, **P<0.01, ***P<0.001). Ctl indicates control.
has recently been reported to exert neuroprotective effects. 50 Exogenous lactate is neuroprotective in an in vivo model of brain ischemia, yet the mechanism of protection triggered by lactate is still unknown, and its mode of action is influenced by the type of anesthetic agent used. 51 Furthermore, ischemia results in a profound (8-10-fold) depletion of all NAD-linked substrates in brain, specifically pyruvate, citrate, α-ketoglutarate, oxaloacetate, fumarate, and malate. 52 In contrast, only succinate concentration was shown to be robustly increased by ≈300% 52 and remain elevated after reperfusion. 53 Because succinate has recently been shown to induce angiogenesis in the developing retina, 24 we proceeded to explore its role and mode of action in post-HI newborn brain vascularization (and hence recovery).
Angiogenesis allows the reestablishment of appropriate blood supply, which in turn allows tissue reoxygenation, facilitates infiltration of relevant inflammatory cells (notably macrophages), and consequently triggers late repair processes. 54 Evidence from human studies demonstrated the beneficial role of increased blood supply, 16 as it correlates with better survival and angiogenesis in general. 55 Numerous bodies of evidence from the present study support angiogenic effects of succinate/GPR91 in brain. After HI, we observed an increase in succinate levels that was associated with an increase in vascular density in mice expressing the succinate receptor. GPR91dependent angiogenesis was coupled to a substantial decrease in the penumbral, as well as the core infarct size; this was not observed in GPR91 -/mice, implicating GPR91 as a regulator of angiogenesis. Injection of succinate in WT mice led to an approximate 2-fold increase in vascular density not observed in GPR91 -/mice. These in vivo results are supported by ex vivo experiments demonstrating a similar 30% increase in vascular density after treatment with succinate. Concordantly, administration of succinate before performing the HI model increased brain vascular density and correspondingly reduced infarct size. The robust angiogenic effects of succinate/GPR91 result from an induction of various angiogenic factors, as corroborated in vitro on cultured neuronal and astrocyte cell lines.
An important feature of this study applies to the mechanism by which GPR91 induces angiogenic factors to exert a beneficial neovascularization. It is known that GPR91 can signal via prostaglandins, 28 and PGE 2 acting via EP 4 has been shown to affect retinal angiogenesis [32] [33] [34] [35] and inhibit apoptosis. 56,57 PGE 2 was increased after succinate injection in WT mice but not in GPR91 -/-; of course, prostaglandin synthesis after HI arises through activation of various pathways, foremost by oxidant stress, inflammatory factors, excitatory mediators, 30, 58, 59 in addition to succinate/GPR91. In neurons and astrocytes, succinate also stimulated PGE 2 formation, which resulted in a dose-dependent induction of VEGF mRNA. 60 In addition, succinate-induced VEGF mRNA expression was markedly diminished by prostaglandin synthase inhibitor indomethacin and by the selective EP 4 antagonist L-161982 but not by the nonspecific EP 1,2,3 nonspecific antagonist AH6809. Our findings are consistent with a robust expression of EP 4 in neurons and in endothelial cells after cerebral ischemia, suggesting a protective sensory cellular mechanism. 61 Along these lines, PGE 2 and EP 4 agonists have recently been patented as a method to treat ischemic episodes (US 2010/0267826 A1).
In summary, our findings unveil a novel concept in post-HI brain vascularization and recovery through actions of metabolic intermediates acting via a specific receptor, namely the succinate receptor GPR91 ( Figure 6 ). Current treatments of HI stroke are mostly limited to supportive therapy, with an effort at protecting neuronal function by preventing hyperthermia or hypoglycemia, normalizing perfusion and ventilation parameters, and recanalizing obstructed arteries (in adults). 62, 63 Other approaches focus on reducing the extent of the injury, such as with the use of inhibitors of excitatory and inflammatory mediators or administration of cytoprotective growth factors. 64 By considering the development of combinatorial therapies to restrict and relieve injury to the brain, it is likely that one would increase the therapeutic window for prevention, rescue, and repair. Pharmacological modulation of pathways involved in the natural recovery process could provide formidable tools to treat these patients. Hence, our observations lend support to the idea that the identification of specific receptors conveying signaling of metabolic intermediates in brain recovery offers potentially important targets to develop therapeutic interventions to optimize poststroke recovery. Considering that succinate accumulates only transiently after HI insult, longer acting agonists of GPR91 may exert more favorable benefits.
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